Education
About Us
Working with TipRanks
Follow Us
TransMedics Group Inc (TMDX)
NASDAQ:TMDX
Total Valuation
TransMedics Group has a market cap or net worth of $4.13B. The enterprise value is ―.
Market Cap$4.13B
Enterprise Value―
Share Statistics
TransMedics Group has 33,833,790 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding33,833,790
Owned by Insiders3.58%
Owned by Institutions24.32%
Financial Efficiency
TransMedics Group’s return on equity (ROE) is 0.16 and return on invested capital (ROIC) is 4.98%.
Return on Equity (ROE)0.16
Return on Assets (ROA)0.04
Return on Invested Capital (ROIC)4.98%
Return on Capital Employed (ROCE)0.05
Revenue Per Employee606.51K
Profits Per Employee0.00
Employee Count728
Asset Turnover0.55
Inventory Turnover3.85
Valuation Ratios
The current PE Ratio of TransMedics Group is 58.42. TransMedics Group’s PEG ratio is 8.04.
PE Ratio58.42
PS Ratio0.00
PB Ratio10.08
Price to Fair Value9.06
Price to FCF-28.52
Price to Operating Cash Flow47.21
PEG Ratio8.04
Income Statement
In the last 12 months, TransMedics Group had revenue of 441.54M and earned 35.46M in profits. Earnings per share was 1.07.
Revenue441.54M
Gross Profit262.08M
Operating Income37.50M
Pretax Income35.78M
Net Income35.46M
EBITDA69.95M
Earnings Per Share (EPS)1.07
Cash Flow
In the last 12 months, operating cash flow was 48.80M and capital expenditures -129.74M, giving a free cash flow of -80.94M billion.
Operating Cash Flow48.80M
Free Cash Flow-80.94M
Free Cash Flow per Share-2.39
Dividends & Yields
TransMedics Group pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.43
52-Week Price Change-9.72%
50-Day Moving Average82.25
200-Day Moving Average99.44
Relative Strength Index (RSI)82.02
Average Volume (3m)1.32M
Important Dates
TransMedics Group upcoming earnings date is Jul 31, 2025, TBA Not Confirmed.
Last Earnings DateMay 8, 2025
Next Earnings DateJul 31, 2025
Ex-Dividend Date―
Financial Position
TransMedics Group as a current ratio of 8.30, with Debt / Equity ratio of 200.75%
Current Ratio8.30
Quick Ratio7.52
Debt to Market Cap0.22
Net Debt to EBITDA1.75
Interest Coverage Ratio2.60
Taxes
In the past 12 months, TransMedics Group has paid 316.00K in taxes.
Income Tax316.00K
Effective Tax Rate<0.01
Enterprise Valuation
TransMedics Group EV to EBITDA ratio is 31.37, with an EV/FCF ratio of 44.96.
EV to Sales4.97
EV to EBITDA31.37
EV to Free Cash Flow44.96
EV to Operating Cash Flow44.96
Balance Sheet
TransMedics Group has $336.65M in cash and marketable securities with $458.92M in debt, giving a net cash position of $122.27M billion.
Cash & Marketable Securities$336.65M
Total Debt$458.92M
Net Cash$122.27M
Net Cash Per Share$3.61
Tangible Book Value Per Share$6.47
Margins
Gross margin is 59.31%, with operating margin of 8.49%, and net profit margin of 8.03%.
Gross Margin59.31%
Operating Margin8.49%
Pretax Margin8.10%
Net Profit Margin8.03%
EBITDA Margin15.84%
EBIT Margin11.37%
Analyst Forecast
The average price target for TransMedics Group is $114.67, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$114.67
Price Target Upside-5.86% Downside
Analyst ConsensusModerate Buy
Analyst Count8
Revenue Growth Forecast64.43%
EPS Growth Forecast―